US LNG exports surge but will buyers in China turn up?
Matthew Campobasso, General Counsel at Enfusion , Inc. (NYSE:ENFN), a fintech company with a market capitalization of $1.46 billion and strong liquidity metrics according to InvestingPro, recently sold a portion of his holdings in the company. According to a recent SEC filing, Campobasso sold 1,695 shares of Class A Common Stock on March 5, 2025. The shares were sold at a weighted average price of $11.375, amounting to a total transaction value of $19,280. Following this sale, Campobasso retains ownership of 70,946 shares in Enfusion. It’s important to note that this transaction was conducted to cover tax withholding obligations related to the issuance of shares, rather than being a discretionary trade by Campobasso. The stock is currently trading near its 52-week high of $11.80, having gained approximately 40% over the past six months. For comprehensive insider trading analysis and 12 additional key insights, visit InvestingPro.
In other recent news, Enfusion Inc. has announced its fourth-quarter results for 2024, coinciding with the company’s acquisition agreement with Clearwater Analytics at a price of $11.25 per share. This acquisition has become a focal point for analysts, with Stifel maintaining a Hold rating and aligning its price target with the acquisition offer. Morgan Stanley (NYSE:MS) has downgraded Enfusion from Overweight to Equal-weight, also setting the price target to $11.25, citing the acquisition as a catalyst for the adjustment. The acquisition price represents a 13% premium over Enfusion’s previous closing price and values the company at approximately 6.4 times its projected FY25 enterprise value/revenue. Analysts from Stifel have expressed that the acquisition price is fair and have noted a low likelihood of competing bids. Morgan Stanley’s analysis highlights that the acquisition might expedite value realization for shareholders while addressing concerns about Enfusion’s market position. Investors are paying close attention as these developments unfold, with the acquisition setting a clear benchmark for Enfusion’s stock value.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.